行情

TRIL

TRIL

Trillium治疗
NASDAQ

实时行情|Nasdaq Last Sale

2.670
-0.160
-5.65%
盘后: 2.600 -0.07 -2.62% 19:58 01/17 EST
开盘
2.800
昨收
2.830
最高
2.960
最低
2.510
成交量
303.85万
成交额
--
52周最高
3.900
52周最低
0.2405
市值
7,486.37万
市盈率(TTM)
-1.8746
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TRIL 新闻

  • B站“出圈”,Z世代的注意力经济怎么做
  • 第一财经.2小时前
  • 脱欧后布局全球市场?英首相拟同多国进行贸易谈判
  • 中国新闻网.3小时前
  • WEF报告:全球一半的GDP适度或高度依赖大自然
  • 第一财经.3小时前
  • 刘强东:京东员工已超21万人 CHO正牵头制定京东家法
  • 澎湃新闻.4小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

TRIL 简况

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
展开

Webull提供Trillium Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。